Description
Description
This page contains brief details about the drug nilotinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The U.S. FDA-approved Aprepitant for the treatment of chronic myeloid leukemia (CML) on October 29, 2007.
Mechanism of Action of Nilotinib
BCR-ABL tyrosine kinase is responsible for the uncontrolled division of cells in the CML. Nilotinib disrupts the signaling route of the protein kinase enzyme which targets the BCR-ABL protein and inhibits the growth and spread of cancer cells.
Uses of Nilotinib
This medicine is used to treat a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph-positive CML), a blood cancer with abnormal production of WBC. In adult and pediatric patients, it is used in a patient who is newly diagnosed with Chronic Myeloid Leukemia (CML) and those facing side effects from previous treatment. Additionally, it is also used in patients with no longer respond to the previous treatment including Imatinib.
Nilotinib Dosage available
Take Nilotinib as advised by your physician. Swallow the medicine with a glass of water. Do not crush, chew, or open the medicine. Your doctor will decide the correct dose and duration for you based on your age, body weight, and disease condition. Do not stop taking Nilotinib unless your doctor advises you to stop.
